

SARS-COV-2 TESTING

ABBOTT ARCHITECT® ANTIBODY ASSAY

- ▶ Chemiluminescent microparticle immunoassay (CMIA)
- ▶ Qualitative detection of IgG antibodies to SARS-CoV-2
- ▶ This test is recommended for clinical laboratory use, and is utilized for clinical evaluation of people recovered from infection who are potential SARS-CoV-2 plasma donors
- ▶ Specimen type can be serum or plasma
- ▶ Result will be P (positive) or N (negative) with the option to receive the calculated index value
- ▶ Assay is only for use under the Food and Drug Administration's Emergency Use Authorization
- ▶ Not a neutralizing assay

SARS-COV-2 IGG ANTIBODY ELISA ASSAY

- ▶ Laboratory-developed ELISA assay
- ▶ Manual assay with limited testing capacity
- ▶ IgG antibody titer detecting assay
- ▶ 1:80 and 1:160 dilution
- ▶ Detects anti-RBD (RBD is a portion of the receptor-binding domain found on human coronavirus spike proteins)
- ▶ Specimen collected in EDTA plasma collection tubes
- ▶ Samples collected from donors can be held at room temperature and plasma separated within 24 hours
- ▶ Separated plasma can be refrigerated (2-8°C) for an additional 24 hours. Separated plasma should be frozen after 48 hours of refrigerated storage
- ▶ Detectable or non-detectable result at each dilution
- ▶ Not a neutralizing assay

Pricing Available from your Corporate Account Executive